IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.
The IXICO Platform deploys the very latest disease-specific algorithms to create reliable clinical data and precision insights that can help accelerate R&D decision making, de-risk clinical research and maximise the potential of drug development programmes.
IXICO has built a global reputation as a leading end-to-end Imaging Contract Research Organisation (iCRO) expertly managing and analysing neurological clinical trials.
The Company is a key part of the global neurological disease research community with a 20-year proven track record in the biopharmaceutical industry working with leading pharma companies, innovative biotech’s, scientific consortia and non-profit organisations.
The IXICO Platform is tailor-made for neurological diseases reliably managing global clinical trials data, precisely reading radiological scans and measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer’s, Huntington’s and Parkinson’s Disease.